Zobrazeno 1 - 10
of 1 928
pro vyhledávání: '"renal anemia"'
Publikováno v:
Expert Opinion on Pharmacotherapy; Jul2024, Vol. 25 Issue 10, p1291-1299, 9p
Autor:
Guoguang Gu, Yanping Li, Yunyun Hu, Hengyi Zhao, Xingdong Wang, Xiaomin Li, Xinran Zhang, Hong Zhu, Xiaohua Dai, Xingxing Liu, Liyan Miao, Jianguo Zhu, Yongfu Hang
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
AimsTo investigate the prevalence and influencing factors of drug-related problems (DRPs) in inpatients with kidney disease to provide reference data for pharmaceutical care.MethodsThe basic information, diagnoses, and medication reconciliation (MR)
Externí odkaz:
https://doaj.org/article/9c0cee5e535d40bb879faea6517d5a80
Autor:
Jie Liu, Shuang Li, Fan Yang, Tianyu Li, Rui Li, Yousuf Waheed, Chen Meng, Shulin Li, Kun Liu, Yanshan Tong, Haisheng Xu, Chuankuo Tian, Xinglei Zhou
Publikováno v:
The Korean Journal of Internal Medicine, Vol 39, Iss 3, Pp 488-500 (2024)
Background/Aims Roxadustat, an oral medication for treating renal anemia, is a hypoxia-inducible factor prolyl hydroxylase inhibitor used for regulating iron metabolism and promoting erythropoiesis. To investigate the efficacy and safety of roxadusta
Externí odkaz:
https://doaj.org/article/f3c4c542145e48ca882452efcb86fd45
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract The determinants of roxadustat treatment failure in renal anemia remain elusive. This study sought to develop a nomogram for predicting the risk of treatment failure of roxadustat in peritoneal dialysis (PD) with renal anemia. A retrospectiv
Externí odkaz:
https://doaj.org/article/9399abba32f14e8d86e6659482ce286a
Autor:
Nobuaki Ariyoshi, Fumiaki Higashijima, Makiko Wakuta, Tadahiko Ogata, Manami Ohta, Kazuhiro Kimura
Publikováno v:
Case Reports in Ophthalmology, Vol 15, Iss 1, Pp 256-264 (2024)
Introduction: Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, used in the treatment of renal anemia, hold the potential to increase the production of vascular endothelial growth factors. Therefore, HIF-PH inhibitors may exacerbate re
Externí odkaz:
https://doaj.org/article/a822da87b0d04083a001a2bef00fe2df
Publikováno v:
Kidney Diseases, Pp 1-7 (2024)
Introduction: Roxadustat, the first-in-class drug for the treatment of renal anemia, has demonstrated efficacy in renal anemia with microinflammation. Additional data are needed regarding the efficacy of roxadustat on renal anemia with systemic macro
Externí odkaz:
https://doaj.org/article/3f8c81ff1608446e8f6344cddb7a01f8
Autor:
Takahiro Kambara, Rei Shibata, Yuusuke Sakamoto, Teruhiro Sakaguchi, Hiroyuki Osanai, Yoshihito Nakashima, Hiroshi Asano, Toyoaki Murohara, Masayoshi Ajioka
Publikováno v:
BMC Research Notes, Vol 17, Iss 1, Pp 1-6 (2024)
Abstract Objective Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors are a new class of anti-anemia agents. We retrospectively evaluated the safety and efficacy of HIF-PH inhibitors in patients with heart failure (HF) complicated by ane
Externí odkaz:
https://doaj.org/article/5c3ebe4c0b8d4e92be810fe3b7070e1e